Oruka Therapeutics Inc. Common Stock vs ThredUp Inc — how do they compare? Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B), while ThredUp Inc trades at $2.2 (market cap $303.38M). The key difference: Oruka Therapeutics Inc. Common Stock is far larger — about 17.1× ThredUp Inc's market cap, and Oruka Therapeutics Inc. Common Stock is trading nearer its 52-week high, ThredUp Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Oruka Therapeutics Inc. Common Stock for 0 Days and ThredUp Inc for 29 Days on average.
| ORKA | TDUP | |
|---|---|---|
Market Cap | $5.18B | $303.38M |
Volume | 490,798 | 1,426,025 |
Sector | Health | Consumer Cyclical |
52-Week High | $113.08 | $9.38 |
52-Week Low | $26.19 | $2.12 |
Typical Hold Time | 0 Days | 29 Days |
Enterprise Value | $4.31B | $301.56M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ThredUp (TDUP) trades at $2.2, down 11.29% in the last session, with a bullish technical signal from moving averages but mixed oscillators. The company reported record Q2 2026 revenue of $90.8 million, up 17% year-over-year, but missed EPS estimates and cut full-year revenue guidance. Cash flow from operations improved to $10.65 million in 2025, though net income remains negative. Analyst consensus is 57% buy, with no sell ratings, but recent news highlights promotional headwinds and a securities investigation.
The outlook is cautious; revenue growth and high gross margins are positives, but persistent losses, weak guidance, and legal risks pose challenges. The stock's low price-to-sales ratio of 0.88 may attract value investors, yet profitability concerns and negative ROE of -36.76% underscore significant execution risk. Investors should weigh strong analyst support against fundamental weaknesses and market sentiment shifts.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app, and RaaS partners.
Read more on TDUP →